A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04138875
Collaborator
(none)
25
Enrollment
2
Locations
2
Arms
23
Anticipated Duration (Months)
12.5
Patients Per Site
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction.

The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).

Detailed Description

Post-Transplant Lymphoproliferative Disorders (PTLD) are defined by the revised 2017 edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues as "lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in a recipient of a solid organ, bone marrow or stem cell allograft". Within this definition 4 distinct categories exist, including: (1) Non-destructive PTLDs (plasmacytic hyperplasia, infectious mononucleosis, and florid follicular hyperplasia) (2) Polymorphic PTLD; (3) Monomorphic PTLD and (4) Classical Hodgkin Lymphoma type PTLD.

The incidence of PTLD varies between different transplanted organs. Across all transplants monomorphic PTLD is the most common accounting for 75% of all cases. Lymphoma derived of B- cell origin account for the majority of cases (70%), while T-cell neoplasms represent a small minority (5%). Within monomorphic PTLD 50% of cases demonstrate association with the Epstein Barr Virus (EBV). Polymorphic PTLD accounts for 15-20% of all PTLD cases with the majority demonstrating EBV involvement. Early lesions account for 5% of PTLD and are all uniformly associated with EBV as are all the cases of Classic Hodgkin Lymphoma type PTLD.

The current understanding of the pathogenesis of PTLD is incomplete. Despite concerted efforts, the investigators are unable to predict who will develop PTLD and do not understand why only 1 - 2% of all transplant recipients develop these disorders.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
This is an open label, sequential, risk stratified study.This is an open label, sequential, risk stratified study.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Active Comparator: Low Risk

Low risk patients (those in complete response (CR) after induction) will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 of 21 day cycles, for 4 cycles.

Drug: Rituximab
Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
Other Names:
  • Rituxan
  • Drug: Brentuximab Vedotin
    Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
    Other Names:
  • Adcetris
  • Active Comparator: High Risk

    High risk patients (those who do not achieve a CR after induction), will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 and bendamustine (90mg/m2) on day 1-2 of 21 day cycles for up to 8 cycles. Interim imaging will be performed in cycle 4 (days 14-21) and patients achieving CR will receive additional 2 cycles for a total of 6, patients achieving partial response (PR) will receive 4 additional cycles.

    Drug: Rituximab
    Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
    Other Names:
  • Rituxan
  • Drug: Brentuximab Vedotin
    Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
    Other Names:
  • Adcetris
  • Drug: Bendamustine
    Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
    Other Names:
  • Bendamustine hydrochloride
  • Outcome Measures

    Primary Outcome Measures

    1. Overall response rate (ORR) (complete + partial response rate) [Up to 84 days of treatment (4 cycles of treatment)]

      Overall response rate (ORR) (complete + partial response rate) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients.

    2. Progression free survival (PFS) rate [Up to 84 days of treatment (4 cycles of treatment)]

      Progression free survival (PFS) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients.

    Secondary Outcome Measures

    1. ORR at the end of the induction phase [Up to 126 days of treatment (6 cycles of treatment)]

      ORR at the end of the induction phase with rituximab and brentuximab vedotin (RBv) in patients

    2. Duration of response (DOR) [Up to 84 days of treatment (4 cycles of treatment)]

      duration of response (DOR) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients with newly diagnosed polymorphic and monomorphic CD20+ and CD 30+ PTLD.

    3. Overall survival (OS) [3 years]

      Overall survival (OS) of the combination of rituximab, brentuximab vedotin +/-bendamustine in patients with newly diagnosed polymorphic and monomorphic CD20+ and CD 30+ PTLD

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age ≥ 18 and ≤ 70 at the time of signing informed consent

    2. Patient must have histologically confirmed newly diagnosed polymorphic or monomorphic PTLD defined according to the 2016 World Health Organization (WHO) classification criteria.

    3. Diagnostic archival tissue available for review and correlative studies

    4. Previous solid organ or allogeneic hematopoietic stem cell transplant

    5. Measurable disease

    6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

    7. Patients must have adequate organ and marrow function

    8. Negative urine or serum pregnancy test for women of childbearing potential

    9. Patients must be able to understand and to sign a written consent document.

    Exclusion Criteria:
    1. Previous treatment for PTLD with the exception of immunosuppression reduction

    2. Known involvement of the central nervous system by the PTLD

    3. Known allergic reactions against foreign proteins

    4. Uncontrolled inter-current illness including active infection, acute graft versus host disease and/or transplant organ rejection

    5. Active concurrent malignancy with the exception of non-melanoma skin cancer, carcinoma in situ of the cervix or localized prostate cancer

    6. Severe non-compensated diabetes mellitus

    7. Pre-existing neuropathy grade 2 or greater

    8. Pregnant or lactating

    9. Psychiatric illness / social situations that would limit compliance with study requirements

    10. Patients with previous hypersensitivity to Rituximab

    11. Known HIV positive.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Yale UniversityNew HavenConnecticutUnited States06519
    2Mayo ClinicRochesterMinnesotaUnited States55902

    Sponsors and Collaborators

    • Yale University

    Investigators

    • Principal Investigator: Francesa Montanari, MD, Yale University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    FRANCESCA MONTANARI, Assistant Professor of Medicine, Yale University
    ClinicalTrials.gov Identifier:
    NCT04138875
    Other Study ID Numbers:
    • 2000029609
    First Posted:
    Oct 25, 2019
    Last Update Posted:
    Nov 1, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 1, 2021